Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN
| Autor: | Lisa Richmond, Ron Shaoul, Neil Shah, Dan Turner, Tim G. J. de Meij, Johanna C. Escher, Lissy de Ridder, Amit Assa, Oren Ledder, Victorien M. Wolters, Javier Martín-de-Carpi, Astor Rodrigues, Arie Levine, Carsten Posovszky, Christian Jakobsen, Shlomi Cohen, Mira Friedman, Jiri Bronsky, Kaija-Leena Kolho, Dror S. Shouval, Frank M. Ruemmele, Holm H. Uhlig |
|---|---|
| Přispěvatelé: | Amsterdam Reproduction & Development (AR&D), Pediatric surgery, AGEM - Digestive immunity, AII - Inflammatory diseases, Pediatrics |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics paediatric Adolescent Vedolizumab medicine.medical_treatment Antibodies Monoclonal Humanized Inflammatory bowel disease Gastroenterology 03 medical and health sciences 0302 clinical medicine Crohn Disease Maintenance therapy inflammatory bowel disease Interquartile range Internal medicine Journal Article medicine Humans Child Retrospective Studies Colectomy business.industry General Medicine Inflammatory Bowel Diseases medicine.disease Ulcerative colitis Treatment Outcome Child Preschool 030220 oncology & carcinogenesis Concomitant Cohort Colitis Ulcerative Female 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | JOURNAL OF CROHNS & COLITIS r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu instname r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu Fundació Sant Joan de Déu Journal of Crohn's and Colitis, 11(10), 1230-1237. Elsevier Journal of Crohn's & Colitis, 11(10), 1230. Elsevier Journal of Crohn's and Colitis, 11(10), 1230-1237. Oxford University Press Ledder, O, Assa, A, Levine, A, Escher, J C, de Ridder, L, Ruemmele, F, Shah, N, Shaoul, R, Wolters, V M, Rodrigues, A, Uhlig, H H, Posovsky, C, Kolho, K L, Jakobsen, C, Cohen, S, Shouval, D S, de Meij, T, Martin-de-Carpi, J, Richmond, L, Bronsky, J, Friedman, M & Turner, D 2017, ' Vedolizumab in paediatric inflammatory bowel disease : A retrospective multi-centre experience from the paediatric IBD porto group of ESPGHAN ', Journal of Crohn's and Colitis, vol. 11, no. 10, pp. 1230-1237 . https://doi.org/10.1093/ecco-jcc/jjx082 |
| ISSN: | 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjx082 |
| Popis: | Background: Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with inflammatory bowel disease [IBD], but the data in paediatrics are limited. We describe the short-term effectiveness and safety of vedolizumab in a European multi-centre paediatric IBD cohort. Method: Retrospective review of children [aged 2–18 years] treated with vedolizumab from 19 centres affiliated with the Paediatric IBD Porto group of ESPGHAN. Primary outcome was Week 14 corticosteroid-free remission [CFR]. Results: In all, 64 children were included (32 [50%] male, mean age 14.5 ± 2.8 years, with a median follow-up 24 weeks [interquartile range 14–38; range 6–116]); 41 [64%] cases of ulcerative colitis/inflammatory bowel disease unclassified [UC/IBD-U] and 23 [36%] Crohn’s disease [CD]. All were previously treated with anti-tumour necrosis factor [TNF] [28% primary failure, 53% secondary failure]. Week 14 CFR was 37% in UC, and 14% in CD [P = 0.06]. CFR by last follow-up was 39% in UC and 24% in CD [p = 0.24]. Ten [17%] children required surgery, six of whom had colectomy for UC. Concomitant immunomodulatory drugs did not affect remission rate [42% vs 35%; p = 0.35 at Week 22]. There were three minor drug-related adverse events. Only 3 of 16 children who underwent endoscopic evaluation had mucosal healing after treatment (19%). Conclusions: Vedolizumab was safe and effective in this cohort of paediatric refractory IBD. These data support previous findings of slow induction rate of vedolizumab in CD and a trend to be less effective compared with patients with UC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|